Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down76.900 -0.600 (-0.774%)
Research Report

21/01/2021 15:12

{I-bank focus}Daiwa starts JD Health (06618) at HK$148.2

[ET Net News Agency, 21 January 2021] Daiwa Research initiated coverage on JD Health
International (JDH) (06618) with a "hold" rating and a target price of HK$148.2.
The research house said JDH is an early mover among China's HealthTech digital new
infrastructure creators. Daiwa views online health services as the "new infrastructure"
that enables external parties with new online business models, and an online pharmacy as
the cash cow that funds the former.
Despite rapid GMV growth for its online pharmacy business (based on existing
infrastructure), Daiwa sees longterm upside in its online health services (new
infrastructure creator), which serves as the digital new infrastructure for potential
HealthTech ecosystems and new business models.
It sees JDH enjoying synergies from its parent in creating digital new infrastructure,
including (1) traffic - JDH can reach the group's over 400m active user accounts, (2)
logistics - JDH provides customers with an enriched product offering and quality delivery
services, leveraging on JD Group's extensive supply chain and national fulfilment network,
and (3) technology - backed by JD Group's core technologies, JDH can further improve its
digitalisation solutions for other healthcare participants. (KL)

Remark: Real time quote last updated: 24/09/2021 13:44
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.